Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2-early breast cancer in China.

Wei, Qiran; Xu, YuTing; Liu, Wei; Guan, Xin.

Afiliação

Wei Q; School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, 211198, Jiangsu, China.
Xu Y; Center for Pharmacoeconomics and Outcomes Research of China Pharmaceutical University, Nanjing, 211198, Jiangsu, China.
Liu W; School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, 211198, Jiangsu, China.
Guan X; Center for Pharmacoeconomics and Outcomes Research of China Pharmaceutical University, Nanjing, 211198, Jiangsu, China.

Cost Eff Resour Alloc ; 21(1): 91, 2023 Nov 27.

Article em En | MEDLINE | ID: mdl-38012661